Trial Profile
Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- Acronyms APRIORI
- 24 Mar 2012 Actual initiation date changed from 1 June 2009 to 4 May 2009 as reported by European Clinical Trials Database.
- 14 Jul 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 26 May 2011 Planned end date changed from 1 Feb 2013 to 1 Jun 2011 as reported by ClinicalTrials.gov.